Bristol-Myers Squibb - A global biopharmaceutical company
INDEX
|
CONTACT US
Argentina
Australia
Austria
Belgium
Brazil
Canada
China
Czech Republic
Denmark
Finland
France
Germany
Greece
Hungary
India
Ireland
Italy
Japan
Korea
Mexico
The Netherlands
Norway
Poland
Portugal
Spain
Sweden
Switzerland
Taiwan
Turkey
United Kingdom
BMS.com-US
Our Company
Our Mission & Commitment
Key Facts
Leadership
Our Operations
Governance
Compliance & Ethics
History
Diversity & Inclusion
Achievements
Business Information
|
R&D
In the Pipeline
Investigational Compound News
Therapeutic Areas of Focus
R&D Organization
Major R&D Facilities
Clinical Trials
Investigator- Sponsored Research
|
Products
Help Paying For Your Medicine
Counterfeit Drugs
Medical Information Inquiries
|
News
Press Releases
Publications
Media Library
Key Facts
Leadership
Financial Reporting
Features
Achievements
Media Contacts
Subscribe to e-mail alerts
|
Investors
Key Facts
Stock Information
SEC Filings
Financial Reporting
Events & Presentations
Shareholder Services
Investor Contacts
|
Partnering
Why Partner With Us?
Areas of Interest
Our Process
Our Partners
Partnering News
Partnering Contact
|
Responsibility
Bristol-Myers Squibb Foundation
Sustainability
Help Paying For Your Medicine
Building Our Communities
Grants & Giving
Position on Key Issues
Transparency
Clinical Trials
Combating Counterfeit Drugs
Disaster Relief & Product Donations
Achievements
Access to Medicines
|
Careers
Job Opportunities
Our Culture
Diversity & Inclusion
Developing Our People
University Recruitment
Achievements
Benefits
Apply Now
ELIQUIS
®
(apixaban)
Approved in Europe
For Prevention of Stroke and Systemic Embolism in Patients with Nonvalvular
Atrial Fibrillation
Press Release
LATEST NEWS
December 4, 2012
Bristol-Myers Squibb Announces Dividend Increase
November 20, 2012
ELIQUIS®(apixaban) Approved in Europe for Prevention of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation
November 14, 2012
Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes
Get RSS News Alerts
Follow us on twitter.com/bmsnews
11/30/2012
Statement on
Avagacestat Development Status
Clinical Trials and Research
Learn about Bristol-Myers Squibb's
Clinical Trial Activities
and
Investigator-Sponsored Research
Need Help Paying for Your
Bristol-Myers Squibb Medicines?
Learn about our
assistance programs
.
Patients and
Caregivers
Learn about clinical trial participation at
Bristol-Myers Squibb
Study Connect
Health Care Professionals
Access
medical information and resources
California Transparency in Supply Chains (PDF)